Francisco J LÃ³pez-Soriano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7895823/publications.pdf

Version: 2024-02-01

174
papers

9,290
citations

28274

55
h-index

48315

88
g-index

178
all docs

178
docs citations

178
times ranked

7832
citing authors

#	Article	IF	Citations
1	Cancer cachexia: understanding the molecular basis. Nature Reviews Cancer, 2014, 14, 754-762.	28.4	991
2	Resveratrol, a Natural Product Present in Wine, Decreases Tumour Growth in a Rat Tumour Model. Biochemical and Biophysical Research Communications, 1999, 254, 739-743.	2.1	246
3	Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology, 2015, 22, 100-106.	3.5	231
4	Inter-tissue communication in cancer cachexia. Nature Reviews Endocrinology, 2019, 15, 9-20.	9.6	191
5	The role of cytokines in cancer cachexia. , 1999, 19, 223-248.		183
6	Cross-talk between skeletal muscle and adipose tissue: A link with obesity?. Medicinal Research Reviews, 2005, 25, 49-65.	10.5	162
7	The role of cytokines in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2009, 3, 263-268.	1.3	162
8	TNF Can Directly Induce the Expression of Ubiquitin-Dependent Proteolytic System in Rat Soleus Muscles. Biochemical and Biophysical Research Communications, 1997, 230, 238-241.	2.1	159
9	IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R674-R683.	1.8	149
10	Anticachectic Effects of Formoterol. Cancer Research, 2004, 64, 6725-6731.	0.9	148
11	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 17-24.	2.4	146
12	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. International Journal of Biochemistry and Cell Biology, 2005, 37, 1084-1104.	2.8	144
13	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 87-93.	7.3	138
14	Tumour necrosis factor-Î± increases the ubiquitinization of rat skeletal muscle proteins. FEBS Letters, 1993, 323, 211-214.	2.8	125
15	Journey from cachexia to obesity by TNF. FASEB Journal, 1997, 11, 743-751.	0.5	123
16	Increased muscle ubiquitin mRNA levels in gastric cancer patients. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 280, R1518-R1523.	1.8	123
17	Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Letters, 1994, 338, 311-318.	2.8	120
18	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 37-43.	7.3	115

#	Article	IF	Citations
19	Cytokines in the pathogenesis of cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 401-406.	2.5	114
20	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2005, 579, 1646-1652.	2.8	109
21	Myostatin: more than just a regulator of muscle mass. Drug Discovery Today, 2012, 17, 702-709.	6.4	105
22	Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Molecular and Cellular Endocrinology, 1998, 142, 183-189.	3.2	104
23	Cancer cachexia: the molecular mechanisms. International Journal of Biochemistry and Cell Biology, 2003, 35, 405-409.	2.8	102
24	Are there any benefits of exercise training in cancer cachexia?. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 73-76.	7.3	102
25	Muscle wasting associated with cancer cachexia is linked to an important activation of the atp-dependent ubiquitin-mediated proteolysis. International Journal of Cancer, 1995, 61, 138-141.	5.1	101
26	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Letters, 1998, 133, 83-87.	7.2	98
27	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2004, 569, 201-206.	2.8	95
28	DNA Fragmentation Occurs in Skeletal Muscle during Tumor Growth: A Link with Cancer Cachexia?. Biochemical and Biophysical Research Communications, 2000, 270, 533-537.	2.1	94
29	The role of uncoupling proteins in pathophysiological states. Biochemical and Biophysical Research Communications, 2002, 293, 1145-1152.	2.1	90
30	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 2036-2046.	2.8	89
31	In the rat, tumor necrosis factor Î± administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. FEBS Letters, 1998, 440, 348-350.	2.8	88
32	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Letters, 2001, 167, 33-38.	7.2	88
33	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 2002, 1570, 33-37.	2.4	87
34	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition, 2005, 21, 977-985.	2.4	86
35	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2770-2778.	2.4	83
36	Effects of Eicosapentaenoic Acid (EPA) Treatment on Insulin Sensitivity in an Animal Model of Diabetes: Improvement of the Inflammatory Status. Obesity, 2011, 19, 362-369.	3.0	80

#	Article	IF	Citations
37	Interleukin-15 increases glucose uptake in skeletal muscle An antidiabetogenic effect of the cytokine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1613-1617.	2.4	79
38	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. International Journal of Oncology, 2013, 43, 886-894.	3.3	79
39	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget, 2015, 6, 43202-43215.	1.8	78
40	The role of cytokines in muscle wasting: Its relation with cancer cachexia. Medicinal Research Reviews, 1992, 12, 637-652.	10.5	77
41	Cancer cachexia: A therapeutic approach. Medicinal Research Reviews, 2001, 21, 83-101.	10.5	75
42	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 95-104.	7.3	72
43	Cachexia: a problem of energetic inefficiency. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 279-286.	7.3	72
44	Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. Antioxidants and Redox Signaling, 2010, 12, 365-380.	5.4	71
45	Anti-Tumour Necrosis Factor-Î± Treatment Interferes with Changes in Lipid Metabolism in a Tumour Cachexia Model. Clinical Science, 1994, 87, 349-355.	4.3	70
46	Anti-TNF Treatment Reverts Increased Muscle Ubiquitin Gene Expression in Tumour-Bearing Rats. Biochemical and Biophysical Research Communications, 1996, 221, 653-655.	2.1	69
47	Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Letters, 1998, 130, 19-27.	7.2	69
48	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Letters, 2007, 245, 144-148.	7.2	68
49	The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends in Pharmacological Sciences, 1996, 17, 223-226.	8.7	67
50	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Letters, 1998, 436, 415-418.	2.8	64
51	Anti-inflammatory therapies in cancer cachexia. European Journal of Pharmacology, 2011, 668, S81-S86.	3.5	63
52	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discovery Today, 2009, 14, 208-213.	6.4	61
53	Catabolic proinflammatory cytokines. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 245-251.	2.5	61
54	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. Journal of Cellular Physiology, 2000, 184, 380-384.	4.1	60

#	Article	IF	Citations
55	Novel approaches to the treatment of cachexia. Drug Discovery Today, 2008, 13, 73-78.	6.4	60
56	Counteracting Inflammation: A Promising Therapy in Cachexia. Critical Reviews in Oncogenesis, 2012, 17, 253-262.	0.4	59
57	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clinical Nutrition, 2007, 26, 614-618.	5.0	58
58	Muscle wasting in cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 221-225.	2.5	56
59	Tumor necrosis factor-Î± exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1542, 66-72.	4.1	55
60	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <scp>II</scp> receptor inhibition and Î²â€•2 agonist. International Journal of Cancer, 2016, 138, 2021-2029.	5.1	55
61	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. International Journal of Molecular Medicine, 2005, 16, 471-6.	4.0	54
62	Effects of interleukin-15 on lipid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 37-42.	2.4	50
63	Cytokines as Mediators and Targets for Cancer Cachexia. Cancer Treatment and Research, 2006, 130, 199-217.	0.5	50
64	Mediators of cachexia in cancer patients. Nutrition, 2019, 66, 11-15.	2.4	50
65	Interleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Letters, 1994, 76, 1-4.	7.2	48
66	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. FEBS Letters, 2005, 579, 717-722.	2.8	48
67	TNF and pregnancy: the paradigm of a complex interaction. Cytokine and Growth Factor Reviews, 1997, 8, 181-188.	7.2	46
68	Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. Frontiers in Physiology, 2017, 8, 92.	2.8	46
69	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 48-59.	7.3	45
70	Comparative effects of Î²2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Letters, 1997, 115, 113-118.	7.2	44
71	The Increased Skeletal Muscle Protein Turnover of the Streptozotozin Diabetic Rat Is Associated with High Concentrations of Branched-Chain Amino Acids. Biochemical and Molecular Medicine, 1997, 61, 87-94.	1.4	44
72	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 315-320.	7.3	44

#	ARTICLE	IF	CITATIONS
73	Catabolic mediators as targets for cancer cachexia. Drug Discovery Today, 2003, 8, 838-844.	6.4	43
74	Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of Î²2-Adrenergic Agonists. Cancer Research, 2007, 67, 6512-6519.	0.9	43
75	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. International Journal of Biochemistry and Cell Biology, 2008, 40, 1674-1678.	2.8	43
76	Nonmuscle Tissues Contribution to Cancer Cachexia. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	43
77	Mechanisms to explain wasting of muscle and fat in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2007, 1, 293-298.	1.3	42
78	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clinical Nutrition, 2007, 26, 239-244.	5.0	42
79	Leptin and tumor growth in rats. , 1999, 81, 726-729.		41
80	The Pharmacological Treatment of Cachexia. Current Drug Targets, 2004, 5, 265-277.	2.1	41
81	Effects of ILâ€•15 on Rat Brown Adipose Tissue: Uncoupling Proteins and PPARs. Obesity, 2008, 16, 285-289.	3.0	40
82	Effects of the beta 2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. Biochimie, 2018, 149, 79-91.	2.6	39
83	Branched-chain amino acids: A role in skeletal muscle proteolysis in catabolic states?. Journal of Cellular Physiology, 2002, 191, 283-289.	4.1	38
84	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 1609-1619.	2.8	38
85	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine, 2003, 22, 1-4.	3.2	37
86	l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clinical Nutrition, 2012, 31, 889-895.	5.0	37
87	TNF-Î± modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Letters, 2002, 175, 181-185.	7.2	33
88	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. FEBS Letters, 2009, 583, 350-356.	2.8	33
89	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncology Reports, 2011, 25, 189-93.	2.6	33
90	Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Letters, 1996, 99, 7-14.	7.2	32

#	Article	IF	Citations
91	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. Journal of Nutritional Biochemistry, 2000, 11, 431-435.	4.2	31
92	Calpain-3 gene expression is decreased during experimental cancer cachexia. Biochimica Et Biophysica Acta - General Subjects, 2000, 1475, 5-9.	2.4	31
93	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncology Letters, 2012, 3, 185-189.	1.8	31
94	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. FEBS Letters, 2001, 505, 255-258.	2.8	29
95	Antiproteolytic effects of plasma from hibernating bears: A new approach for muscle wasting therapy?. Clinical Nutrition, 2007, 26, 658-661.	5.0	29
96	Lipid metabolism in tumour-bearing mice:. Molecular and Cellular Endocrinology, 1997, 132, 93-99.	3.2	27
97	Short-term effects of leptin on lipid metabolism in the rat. FEBS Letters, 1998, 431, 371-374.	2.8	27
98	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. Clinical Nutrition, 2010, 29, 733-737.	5.0	27
99	The systemic inflammatory response is involved in the regulation of K+channel expression in brain via TNF-Î±-dependent and -independent pathways. FEBS Letters, 2004, 572, 189-194.	2.8	26
100	The AP-1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia. FEBS Letters, 2006, 580, 691-696.	2.8	26
101	Interleukinâ€15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. Lipids, 2011, 46, 1033-1042.	1.7	25
102	Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Letters, 1995, 91, 73-78.	7.2	24
103	Controversy in Basic Sciences Is TNF Really Involved in Cachexia?. Cancer Investigation, 1997, 15, 47-54.	1.3	24
104	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	2.5	24
105	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor-Î±?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2001, 1499, 249-256.	4.1	23
106	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: Possible involvement on in vivo adipocyte differentiation. International Journal of Molecular Medicine, 2009, 24, 453-8.	4.0	23
107	Sirtuin 1 in skeletal muscle of cachectic tumourâ€bearing rats: a role in impaired regeneration?. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 57-62.	7.3	22
108	Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Letters, 1995, 97, 25-32.	7.2	21

#	Article	IF	Citations
109	Metabolic interrelationships between liver and skeletal muscle in pathological states. Life Sciences, 2001, 69, 1345-1361.	4.3	21
110	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle and Nerve, 2008, 37, 190-195.	2.2	21
111	Lipopolysaccharide (LPS) increases thein vivo oxidation of branched-chain amino acids in the rat: A cytokine-mediated effect. Molecular and Cellular Biochemistry, 1995, 148, 9-15.	3.1	20
112	Impaired voltage-gated K+channel expression in brain during experimental cancer cachexia. FEBS Letters, 2003, 536, 45-50.	2.8	20
113	A differential pattern of gene expression in skeletal muscle of tumorâ€bearing rats reveals dysregulation of excitationâ€“contraction coupling together with additional muscle alterations. Muscle and Nerve, 2014, 49, 233-248.	2.2	20
114	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. PeerJ, 2017, 5, e4109.	2.0	20
115	Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Molecular and Cellular Biochemistry, 1996, 165, 17-23.	3.1	18
116	Targets in clinical oncology: the metabolic environment of the patient. Frontiers in Bioscience - Landmark, 2007, 12, 3024.	3.0	18
117	Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutrition and Metabolism, 2012, 9, 76.	3.0	18
118	A small Cretaceous crocodyliform in a dinosaur nesting ground and the origin of sebecids. Scientific Reports, 2020, 10, 15293.	3.3	18
119	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Letters, 2003, 200, 153-160.	7.2	17
120	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. Journal of Lipid Research, 2013, 54, 3045-3051.	4.2	17
121	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. Frontiers in Physiology, 2017, 8, 184.	2.8	17
122	Intestinal amino acid transport: An overview. International Journal of Biochemistry & Cell Biology, 1990, 22, 931-937.	0.5	16
123	Mechanism for the increased skeletal muscle protein degradation in the obese zucker rat. Journal of Nutritional Biochemistry, 1999, 10, 244-248.	4.2	16
124	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: A role in muscle wasting?. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 253-258.	2.4	16
125	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. Experimental and Therapeutic Medicine, 2011, 2, 731-735.	1.8	16
126	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia. , 2011, , 9-35.		16

#	Article	IF	Citations
127	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 2007, 30, 1239-45.	3.3	15
128	Tumour necrosis factor-Î± does not cross the rat placenta. Cancer Letters, 1998, 128, 101-104.	7.2	14
129	A flow cytometric study of the rat Yoshida AH-130 ascites hepatoma. Cancer Letters, 1993, 72, 169-173.	7.2	13
130	Neutral amino acid transport in placental plasma membrane vesicles in the late pregnant rat: Evidence for a B0-like transport system. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1997, 71, 85-90.	1.1	13
131	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817-9.	4.0	13
132	Sepsis induces DNA fragmentation in rat skeletal muscle. European Cytokine Network, 2003, 14, 256-9.	2.0	12
133	Sequential changes in lipoprotein lipase activity and lipaemia induced by the Yoshida AH-130 ascites hepatoma in rats. Cancer Letters, 1997, 116, 159-165.	7.2	11
134	TNF and AIDS: Two sides of the same coin?. Medicinal Research Reviews, 1995, 15, 533-546.	10.5	10
135	Metabolic effects of tumour necrosis factor-Î± on rat brown adipose tissue. Molecular and Cellular Biochemistry, 1995, 143, 113-118.	3.1	10
136	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. Clinical Nutrition, 2011, 30, 33-37.	5.0	10
137	Differential structural features in soleus and gastrocnemius of carnitineâ€treated cancer cachectic rats. Journal of Cellular Physiology, 2020, 235, 526-537.	4.1	10
138	Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 1994, 87, 123-130.	7.2	9
139	The animal cachexia score (ACASCO). Animal Models and Experimental Medicine, 2019, 2, 201-209.	3.3	9
140	The enzymatic activities of branched-chain amino acid catabolism in tumour-bearing rats. Cancer Letters, 1992, 61, 239-242.	7.2	8
141	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963-7.	4.0	8
142	Emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs, 2007, 12, 555-570.	2.4	7
143	Oxidation of branched-chain amino acids in tumour-bearing rats. Biochemical Society Transactions, 1989, 17, 1044-1045.	3.4	6
144	Leptin levels and gene expression during the perinatal phase in the rat. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 81, 95-100.	1.1	5

#	Article	IF	Citations
145	The Role of Cytokines in Cancer Cachexia. , 2006, , 467-475.		5
146	Patterns of gene expression in muscle and fat in tumorâ€bearing rats: Effects of CRF2R agonist on cachexia. Muscle and Nerve, 2010, 42, 936-949.	2.2	5
147	Effects of formoterol on protein metabolism in myotubes during hyperthermia. Muscle and Nerve, 2011, 43, 268-273.	2.2	5
148	Omegaâ€3 and omegaâ€3/curcuminâ€enriched fruit juices decrease tumour growth and reduce muscle wasting in tumourâ€bearing mice. JCSM Rapid Communications, 2018, 1, 1-10.	1.6	5
149	Tumour necrosis factor-Î± alters the blood compartmentation of amino acids in the rat. Cancer Letters, 1993, 72, 71-76.	7.2	4
150	Leptin administration to lactating rats is unable to induce changes in lipid metabolism in white adipose tissue or mammary gland. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1999, 84, 93-97.	1.1	4
151	A revision of the first Asteropyginae (Trilobita; Devonian). Geobios, 2014, 47, 281-289.	1.4	4
152	Effects of tumour necrosis factor on hepatic amino acid uptake. Biochemical Society Transactions, 1989, 17, 1045-1046.	3.4	3
153	In vitro alanine utilization by rat interscapular brown adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 1990, 1036, 6-10.	2.4	3
154	The role of insulin in the intestinal absorption of glucose in the rat. International Journal of Biochemistry & Cell Biology, 1992, 24, 631-636.	0.5	3
155	The effects of tumour necrosis factor-Î± on circulating amino acids in the pregnant rat. Cancer Letters, 1994, 79, 27-32.	7.2	3
156	Î±-Adrenergic receptors may contribute to the hypertriglyceridemia associated with tumour growth. Cancer Letters, 1996, 110, 213-216.	7.2	3
157	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. E-SPEN Journal, 2012, 7, e135-e138.	0.5	3
158	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. JCSM Rapid Communications, 2018, 1, 1-15.	1.6	3
159	Tumor Growth Influences Skeletal Muscle Protein Turnover in the Pregnant Rat. Pediatric Research, 1998, 43, 250-255.	2.3	3
160	The appearance of 2,3-butanediol in the chronic ethanol treated pregnant rat. Drug and Alcohol Dependence, 1986, 18, 335-339.	3.2	2
161	Glucose handling by hepatocytes from obese Zucker rats. Bioscience Reports, 1991, 11, 285-292.	2.4	2
162	Amino acid metabolism in several tissues of the obese Zucker rat as indicated by the tissue accumulation of Î±-amino[1-14C]isobutyrate. Molecular and Cellular Biochemistry, 1992, 110, 155-159.	3.1	2

#	ARTICLE	IF	CITATIONS
163	Marked hyperlipidaemia in rats bearing the Yoshida AH-130 ascites hepatoma. Biochemical Society Transactions, 1995, 23, 492S-492S.	3.4	2
164	Lipogenesis in rat tissues following carbohydrate refeeding: spleen lipogenesis is modulated by insulin. Molecular and Cellular Biochemistry, 1997, 175, 149-152.	3.1	2
165	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. International Journal of Molecular Medicine, 2004, 14, 719.	4.0	2
166	Cancer Cachexia and Fat Metabolism. , 2006, , 459-466.		2
167	The effects of tumour growth on circulating amino acids in the late pregnant rat. Cancer Letters, 1995, 88, 21-25.	7.2	1
168	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2002, 188, 53-58.	7.2	1
169	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. ChemInform, 2005, 36, no.	0.0	1
170	Lack of Synergy Between Î²-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. OncoTargets and Therapy, 2021, Volume 14, 1953-1959.	2.0	1
171	Metabolism of glucose in isolated intestinal cells from obese zucker rats. Nutrition Research, 1992, 12, 949-954.	2.9	0
172	Hepatic Transport of Gluconeogenic Substrates During Tumor Growth in the Rat. Cancer Investigation, 2001, 19, 248-255.	1.3	0
173	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
174	Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, 275-280.	1.1	0